See the DrugPatentWatch profile for fondaparinux
The NDC number 64757 is associated with Fondaparinux Sodium Injection, a synthetic anticoagulant medication. This drug is used to prevent blood clots in certain patients, such as those who have undergone hip fracture surgery or abdominal surgery, and those with acute pulmonary embolism or deep vein thrombosis [1].
What is Fondaparinux Sodium Injection?
Fondaparinux Sodium Injection is a synthetic pentasaccharide that selectively inhibits activated factor X (FXa), a key enzyme in the blood coagulation cascade [1]. By inhibiting FXa, it prevents the conversion of prothrombin to thrombin, thereby reducing the formation of blood clots [1]. It is administered subcutaneously.
When does patent exclusivity for Fondaparinux expire?
Patent exclusivity timelines are complex and can involve multiple patents with different expiry dates. For Fondaparinux, DrugPatentWatch.com tracks patent data that would indicate when market exclusivity might end for different formulations or indications [2]. For specific details on Fondaparinux patents and their expiry, consulting a resource like DrugPatentWatch.com is recommended [2].
Are there generic versions of Fondaparinux available?
The availability of generic versions of Fondaparinux depends on patent expiries and regulatory approvals. Once patent protections expire and generic manufacturers receive approval, generic alternatives can become available, potentially impacting pricing and market competition [2].
What are the risks associated with Fondaparinux?
The primary risk associated with Fondaparinux, like other anticoagulants, is bleeding. Patients taking Fondaparinux are at an increased risk of hemorrhage [1]. Other potential adverse effects include anemia and dizziness. It is important for healthcare providers to monitor patients for signs of bleeding or other adverse reactions.